KL-VS杂合性与APOE4携带者阿尔茨海默病风险关联
本研究合并25个独立AD队列,分析KL-VS杂合性(KL-VSHET+)与APOE4携带者AD风险及β-淀粉样蛋白(Aβ)病理的关联。结果显示,在60岁及以上APOE4携带者中,KL-VSHET+与AD风险降低相关(OR 0.75),60-80岁更显著(OR 0.69),且与转化风险降低及Aβ水平改变相关。
要点
- KL-VSHET+与60岁及以上APOE4携带者AD风险降低相关(OR 0.75)。
- 60-80岁APOE4携带者中保护作用更显著(OR 0.69)。
- KL-VSHET+与APOE4携带者转化为MCI或AD风险降低相关(HR 0.64)。
核心结论
- KL-VSHET+与60-80岁认知正常APOE4携带者的AD风险降低及Aβ负荷减少相关。
研究设计与样本
- 合并25个独立病例对照、家系和纵向AD队列,数据来自公共数据库,2015年9月至2019年9月收集。
- 参与者为60岁及以上非西班牙裔西北欧裔男性及女性,诊断为认知正常、MCI或AD。
主要发现
- 在60岁及以上APOE4携带者中,KL-VSHET+与AD风险降低相关(OR 0.75,95%CI 0.67-0.84,P=7.4×10^-7)。
- 在60-80岁APOE4携带者中,关联更显著(OR 0.69,95%CI 0.61-0.79,P=3.6×10^-8)。
临床怎么用
- KL-VS基因型可结合APOE基因型用于优化临床试验富集和个性化遗传咨询中的AD预测模型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Identification of genetic factors that interact with the apolipoprotein e4 (APOE4) allele to reduce risk for Alzheimer disease (AD) would accelerate the search for new AD drug targets. Klotho-VS heterozygosity (KL-VSHET+ status) protects against aging-associated phenotypes and cognitive decline, but whether it protects individuals who carry APOE4 from AD remains unclear. OBJECTIVES: To determine if KL-VSHET+ status is associated with reduced AD risk and β-amyloid (Aβ) pathology in individuals who carry APOE4. DESIGN, SETTING, AND PARTICIPANTS: This study combined 25 independent case-control, family-based, and longitudinal AD cohorts that recruited referred and volunteer participants and made data available through public repositories. Analyses were stratified by APOE4 status. Three cohorts were used to evaluate conversion risk, 1 provided longitudinal measures of Aβ CSF and PET, and 3 provided cross-sectional measures of Aβ CSF. Genetic data were available from high-density single-nucleotide variant microarrays. All data were collected between September 2015 and September 2019 and analyzed between April 2019 and December 2019. MAIN OUTCOMES AND MEASURES: The risk of AD was evaluated through logistic regression analyses under a case-control design. The risk of conversion to mild cognitive impairment (MCI) or AD was evaluated through competing risks regression. Associations with Aβ, measured from cerebrospinal fluid (CSF) or brain positron emission tomography (PET), were evaluated using linear regression and mixed-effects modeling. RESULTS: Of 36 530 eligible participants, 13 782 were excluded for analysis exclusion criteria or refusal to participate. Participants were men and women aged 60 years and older who were non-Hispanic and of Northwestern European ancestry and had been diagnosed as being cognitively normal or having MCI or AD. The sample included 20 928 participants in case-control studies, 3008 in conversion studies, 556 in Aβ CSF regression analyses, and 251 in PET regression analyses. The genotype KL-VSHET+ was associated with reduced risk for AD in individuals carrying APOE4 who were 60 years or older (odds ratio, 0.75 [95% CI, 0.67-0.84]; P = 7.4 × 10-7), and this was more prominent at ages 60 to 80 years (odds ratio, 0.69 [95% CI, 0.61-0.79]; P = 3.6 × 10-8). Additionally, control participants carrying APOE4 with KL-VS heterozygosity were at reduced risk of converting to MCI or AD (hazard ratio, 0.64 [95% CI, 0.44-0.94]; P = .02). Finally, in control participants who carried APOE4 and were aged 60 to 80 years, KL-VS heterozygosity was associated with higher Aβ in CSF (β, 0.06 [95% CI, 0.01-0.10]; P = .03) and lower Aβ on PET scans (β, -0.04 [95% CI, -0.07 to -0.00]; P = .04). CONCLUSIONS AND RELEVANCE: The genotype KL-VSHET+ is associated with reduced AD risk and Aβ burden in individuals who are aged 60 to 80 years, cognitively normal, and carrying APOE4. Molecular pathways associated with KL merit exploration for novel AD drug targets. The KL-VS genotype should be considered in conjunction with the APOE genotype to refine AD prediction models used in clinical trial enrichment and personalized genetic counseling.
引用
- Belloy ME, Napolioni V, Han SS, et al. Association of Klotho-VS Heterozygosity With Risk of Alzheimer Disease in Individuals Who Carry APOE4. JAMA Neurol. 2020. PMID: 32282020. doi:10.1001/jamaneurol.2020.0414
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。